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he 9p21 Locus and
oronary Heart Disease
nitiator, Promoter, or Precipitator?*
effrey L. Anderson, MD,
enjamin D. Horne, PHD, MPH
urray, Utah
oronary heart disease (CHD), a major cause of worldwide
orbidity/mortality (1), is a multifactorial, multistage dis-
rder to which both environmental and genetic factors
ontribute (Fig. 1) (2). Despite methodologic advances,
ncluding genomewide association studies, progress in elu-
idating CHD genetics has been slow, and the number and
mpact of well-validated associations remain few and mod-
st. One of the major successes in this effort has been the
iscovery of the CHD risk-associated locus at chromosome
p21.3. First reported by several groups in 2007 (3–6), this
ssociation subsequently has been validated by multiple
roups worldwide, across racial and geographic boundaries,
nd independent of traditional risk factors (7).
See page 479
The 9p21 risk variant is common, with nearly 50%
arrying 1 high-risk allele (with a 20% to 40% increase in
isk) and another 20% to 25% carrying 2 alleles (40% to 70%
ncrease in risk) (7,8). Across a 58-kb region at 9p21.3,
everal single nucleotide polymorphisms (SNPs) exist that
ave been associated with various CHD phenotypes, in-
luding a clinical diagnosis of CHD, myocardial infarction
MI), angiographic coronary artery disease (CAD), or a
ixture of these and others. More recent studies suggest
hat this phenotype should be refined to native coronary
therosclerosis but neither to restenotic disease nor MI per
e (Fig. 1) (8–11). However, the mechanism of the risk
ssociation remains unclear. The 9p21.3 chromosome is
ocated in a region that is devoid of transcribed genes but
hat includes a large antisense noncoding ribonucleic acid
ene (ANRIL), which might act as a vascular growth
egulatory element (12).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Cardiovascular Department, Intermountain Medical Center, University
f Utah School of Medicine, Murray, Utah.Given its importance to CAD genetics, a better under-
tanding of the role of 9p21 in coronary pathophysiology is
f interest. In this issue of the Journal, Dandona et al. (13),
rom Ottawa, address the specific question of its impact on
oronary disease burden.
tudy Summary
andona et al. (13) test the hypothesis that the 9p21
ariant promotes coronary atheroma progression. Two
ngiographically-phenotyped patient sets were studied: an
arly onset CAD group (men55 years of age, women65
ears of age, with at least 1 stenosis 50%; n  950), and a
ater-onset group (n  764). Diabetic patients were excluded
o enrich for genetic factors unique to CAD, and the popula-
ion was restricted to patients of European heritage. The SNP
arker chosen for the primary analysis was rs1333049 (3).
Results demonstrated a strong direct association of early
-vessel disease with allele dosage (odds ratio: 1.45 per allele
opy, p  4  104) and, conversely, a strong inverse
ssociation with 1-vessel disease (odds ratio: 0.64, p  2 
05). The investigators then performed several supportive
nalyses: associations were replicated in the older age
opulation, in the inaugural catheterization subgroup, in
atients with early left main disease, in patients requiring
ypass surgery, in the combined early and late cohorts, in
nalyses using the quantitative Gensini and Duke coronary
cores, and in analyses using the linked 9p21 SNP
s9632884. A further analysis included a small number of
ases with 50% stenosis (n  143) and found a linear
rend of allele frequency across 0- to 3-vessel disease.
inally, when CAD patients were stratified by number of
iseased vessels and the association adjusted for baseline
ovariates, 9p21 did not predict MI.
linical interpretation and implications. The Ottawa
nvestigators are to be congratulated on extending the
xploration of 9p21. Whereas other recent studies have
ocused on comparisons between CAD and no-CAD pop-
lations, this study explores genetic associations within a
AD population. Their finding of a dose effect of the
umber of risk alleles for CAD severity in early onset
isease could be replicated in a separate population of older
atients and in multiple subset and combined-set analyses,
ndicating robust internal consistency. Given this, the au-
hors suggest that the deposition of coronary atheroma
ediates the risk of 9p21. An implication of this for future
esearch is that a search for specific mechanisms should
ocus on atherogenesis, not on plaque instability or throm-
osis. They further suggest that a clinical implication may
e the use of 9p21 as a marker to complement traditional
isk assessment in not only primary but also secondary CAD
revention.
These Ottawa data, added to other recent reports and to
ubgroup analyses from earlier studies, appear to conclu-
ively debunk any direct link between 9p21 and MI suscep-
ibility per se (5,8–12). Hence, the risk of 9p21 for MI must
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enesis and not by actual precipitation of MI (Fig. 1).
What potentially remains as controversial is the precise
ole of 9p21 in atherogenesis. Is 9p21 primarily an initiator/
acilitator of CAD or an amplifier/accelerator/promoter (9)?
he Ottawa study argues for the latter (13), whereas at least
earlier studies involving Asian and Caucasian populations
end support to the former (8,9,14,15). Which is correct, or
ould both be true? The authors offer 3 possible explana-
ions for this discrepancy: 1) a skew in earlier studies to
-vessel disease (with limited power for inter-CAD analy-
es); 2) use of different SNP markers for 9p21; and
) inclusion of diabetic patients in earlier studies, hypothesizing
hat diabetes mellitus might interact to obscure the impact of
p21 on CAD burden (16). None of these possibilities alone is
ntuitively compelling, and further explanations also should be
onsidered, including population-specific differences (i.e., dif-
ering genetic background and environmental factors such as
moking, and use of 50% rather than 70% stenosis to
efine severe CAD [8,9]) as well as the play of chance.
evertheless, when all of these factors are accounted for, 9p21
ay finally be shown to play both roles in CAD development:
imited data on risk allele frequency in 0-vessel disease separate
t well away from 1- to 3-vessel disease in the Ottawa study
see their Fig. 3 [13]), supporting a role for 9p21 in CAD
nitiation, and minor numerical trends in our North American
tudy associating 9p21 with disease burden might be amplified
f controlled for the above factors (8). Future prospective
tudies will be required to definitively resolve this question.
The Ottawa study shares limitations with all cross-
ectional, observational studies, including the potential for
election biases and uncontrolled confounding. Its implica-
ions apply strictly to the population and specific SNPs
tudied. Also, the suggestion that the 9p21 marker might be
seful in both primary and secondary clinical risk assessment
ust be validated by prospective clinical studies. Neverthe-
ess, this study importantly contributes to the growing and
Figure 1 Genetic Model of Coronary Heart Disease
Modified from Horne et al. (9) and Hopkins et al. (2). CAD  coronary artery disea
E  environment; G  genes; MI  myocardial infarction; UA  unstable angina.tage-specific understanding of the role of genetics in CHDathogenesis: 9p21 acts to facilitate initiation of coronary
therosclerosis, not to precipitate MI (Fig. 1). Further, at
east in a Canadian, nondiabetic, coronary disease popula-
ion, dosage of the 9p21 rs1333049 high-risk variant also
romotes and predicts CAD burden.
In conclusion, the answer to the question posed in the
itle of the relationship of 9p21 to CHD appears to be
nitiator, yes; promoter, probably; and precipitator, no.
eprint requests and correspondence: Dr. Jeffrey L. Anderson,
ardiovascular Department, Intermountain Medical Center, Uni-
ersity of Utah School of Medicine, 5121 South Cottonwood
treet, Murray, Utah 84107-5701. E-mail: jeffrey.anderson@
mail.org.
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